The difference between a trial and a pharmacy product
Promising research is not a marketing authorisation. Clinical trials test a compound in selected participants under a protocol. Larger trials, safety analysis, manufacturing review and a regulator’s decision may follow. An early result can change; even a successful trial does not give a date when Spanish pharmacies will have a medicine.
Wegovy and Mounjaro already have EU authorisations for specified uses. Retatrutide and CagriSema remain investigational rather than routine prescription options in Spain. The retatrutide trial registry and CagriSema trial registry show ongoing development; they are not shopping listings.
Retatrutide: a strong early signal, with limits
Retatrutide acts on three receptors: GLP-1, GIP and glucagon. In a phase 2 study of 338 adults with obesity, the 12 mg group had an average 24.2% weight decrease at 48 weeks, compared with 2.1% in the placebo group. This is a group average at a studied dose, not a patient forecast. The study was relatively small and shorter than the evidence normally needed for broad use; larger studies and regulatory review matter.
Retatrutide phase 2: average change at 48 weeks
CagriSema and other combinations
CagriSema combines cagrilintide with semaglutide and has been investigated in phase 3 trials. Its proposed mechanism differs from simply increasing a Wegovy dose. Trial status and any eventual regulatory decision should be checked in the trial registry. It is premature to advertise it as available treatment in Spain or to suggest a future price or launch date.
How to follow the field sensibly
- Look for the trial phase, number of participants, comparison group and follow-up time.
- Ask whether the reported number is a group average or the chance of reaching a threshold.
- Check whether the product is authorised in the EU and what it is authorised for.
- Do not buy a compound advertised as an investigational peptide from an unverified seller.
For a current treatment discussion, see Wegovy formats and Mounjaro in Spain.
How to interpret a striking percentage
A trial average is calculated from a group with entry criteria. It is not the outcome for every person: some lose more, some less, and some stop because of side effects or other reasons. A phase 2 result helps choose doses and detect signals, but it cannot establish long-term safety by itself. Later studies can change the estimate and the balance of benefits and risks.
Be wary of “available now” pages that lift a trial percentage and attach it to an online vial. The vial may not be the studied formulation, may not have consistent potency, and may be supplied outside legal safeguards. The most useful update to watch is a regulatory decision for a specified finished medicine, not a seller’s launch announcement.